Altered γ-aminobutyric acid (GABA) function is consistently reported in psychiatric disorders, normal aging and neurodegenerative disorders, and reduced function of somatostatinexpressing GABA interneurons is associated with both mood and cognitive symptoms.
INTRODUCTION
Altered levels and signaling of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter, is frequently reported in multiple psychiatric disorders (depression (1,2), schizophrenia (3), anxiety disorder (4)), normal ageing (5, 6 ) and neurodegenerative disorders (Alzheimer's disease, AD) (6, 7) in multiple brain regions including the prefrontal cortex (8) , anterior cingulate cortex (9) and amygdala (10) . Postmortem studies have associated these GABAergic deficits to a reduction in number and/or loss of function of somatostatin-expressing GABA interneurons in multiple brain regions (see (6) for review). Previous studies showed that impaired inhibition from somatostatin-expressing GABA neurons mediated emotionality (11) (12) (13) and cognitive deficits (14) (15) (16) .
GABA receptors are represented by two classes: GABA A and GABA B receptors. GABA A receptors (GABAA-Rs) are composed of multiple subunits (α, β, γ, δ, ε, θ, π and ) assembled into pentamers (17) forming a chloride channel. GABA released from somatostatin interneurons are thought to signal, in large part, through the α5-containing GABAA-Rs, due to their preferential localization to extrasynaptic distal dendritic regions regulating tonic inhibition (18) (19) (20) (21) , and additionally through the ubiquitously-expressed α1-GABAA-Rs. Benzodiazepines (BZs; such as diazepam, DZP) and imidazobenzodiazepines (IBZDs, such as flumazenil) represent the well-established classes of therapeutics acting on GABAA-Rs. BZs are prescribed to alleviate the burden of anxiety (22) , but have debatable efficacy on the core symptoms of depression such as anhedonia (23) . BZs modulate GABAA-R activity as non-selective positive allosteric modulators (PAMs), via binding between the γ2 and either the α1, α2, α3 or α5 subunit (24) . This broad receptor activity contributes to significant side-effects (sedation, hypnosis, ataxia, addiction, amnesia), limiting their therapeutic potential (25) . However, the relations are not straightforward; for instance, high activity at α1-GABAA-Rs induces sedation and contributes to amnesia, but the same receptor subtype is also proposed to be implicated in cognition (26) . The BZ anxiolytic properties are mediated predominantly by α2-GABAA-Rs (27) . α5-GABAA-Rs have predominant distribution in the neocortex and hippocampus (28) suggesting a role in cognition and emotion (29, 30) . As α5-PAMs can alleviate behavioral emotionality in a mouse model of schizophrenia (31, 32) and depression (33) , or exert procognitive efficacy in old rats (34), we hypothesize that bypassing the somatostatin/GABA interneurons deficiency through enhanced α5-GABAA-R activity may represent a novel target for combined therapeutic actions on mood and cognition.
Based on an IBZD structure (a BZ-imidazol hybrid) we developed ethyl esters of IBZDs with a C(4) R-CH3 substituent that bind preferentially to the α5β2/3γ2 GABAA-Rs (35) (36) (37) and that are active in models targeting schizophrenia (31, 32) and depression (33) but quickly metabolized (38) . Because of their improved metabolic stability and bioavailability as compared to esters, amides are commonly-used replacements (39) . Hence, a series of amides were designed that fit the pharmacophore/receptor model (37) , with increased binding affinity and efficacy at α5-GABAA-Rs, compared to corresponding esters (40) . We describe here the synthesis, pharmacokinetic, functional and behavioral characteristics of four IBZD amide ligands and we predicted that the novel α5-PAMs will have significant antidepressant potential and procognitive activity in adult and old mice, with limited adverse effects.
METHODS AND MATERIALS
Detailed methods are provided in the supplements.
Chemistry
Novel IBZD amide analogs were synthesized based on the structures of the existing ligands relatively selective for α5-GABAA-Rs, i.e. SH-053-2'F-R-CH3 and MP-III-022 (41) . These new ligands contain a chiral (R) C(4)-methyl group and a 2'F pendent phenyl ring, as general structural requirements for improved selectivity at the α5-subtype based on the pharmacophore model (37) . All four amide analogs, referred herein as GL-II-73, GL-II-74, GL-II-75, and GL-II-76, were prepared from the SH-053-2'F-R-CH3 following steps described in the Supplementary Methods and presented in Supplementary Figure S1 .
Electrophysiological recordings
Electrophysiological recordings were performed as described in (42) (Supplementary Methods). Briefly, HEK-293T cells were transiently transfected with mammalian clones of GABAA-Rs. Currents in response to GABA and GABA+ modulators (EC 3-5 GABA) were measured using voltage-clamp recordings in the whole-cell configuration.
Binding studies
Binding studies were performed on human embryonic kidney (HEK) 293 cells following the 
Animals
Young (2-3 months) or old (21-22 months) C57BL/6 mice were kept in normal housing conditions with a 12hr light-dark cycle, water and food ad libitum. Prior to behavioral assessment, animals were handled daily for 5min to reduce acute anxiety-like responses (44) .
Testing took place during the light phase and was conducted in accordance with local ethical commission on animal experiment (see supplementary for details). To induce a cognitive deficit in young mice, animals were subjected to a chronic stress protocol (CS). They were placed, twice a day for 1hr, in a 50ml Falcon® tube perforated on each end to let the animal breathe.
CS was applied for at least 10 days before testing but was not applied on testing days.
Ligand preparation and administration
Ligands were diluted in a vehicle solution containing 85% distilled H 2 O, 14% propylene glycol and 1% Tween-80 to be administered intraperitoneally (i.p.) at a volume of 10ml/kg. Working solutions were prepared at 1, 5 or 10mg/kg and adjusted to body weight before injection. DZP was used as a non-selective GABAA-R PAM with known anxiolytic activity, which does not exert known pro-cognitive effects. DZP was administered i.p. at 1.5mg/kg based on previous studies (45) .
For sub-chronic administration in the drinking water for 10 consecutive days, ligands were diluted in tap-water, stirred overnight at room temperature and provided in glass bottles to tailor for a 30mg/kg daily dose. Bottles were changed every other day to provide freshly-prepared solutions.
Pharmacokinetic characterization
Metabolism studies were performed in human and mouse liver microsomes as described in (46) . Briefly, the test ligands were incubated at 10µM with active or heat-inactivated human or mouse liver microsomes and appropriate cofactors. Aliquots were removed at different time points and assayed using a liquid chromatography/tandem mass spectrometry (LC-MS/MS) analytical method. To obtain pharmacokinetic profiles, mice were treated i.p. at 10mg/kg and sacrificed at different time points (5-to-720min post-injection) for brain and plasma quantification of ligands by ultraperformance LC-MS/MS (47) .
In vitro hydrolytic plasma stability studies
Each ligand stability was tested in vitro at 37 °C, utilizing blank mouse plasma spiked with the respective ligand and internal standard, as described in (39) .
Plasma protein and brain tissue binding studies
The rapid equilibrium dialysis assay used to determine the free fraction of the ligands in mouse plasma and brain tissue was as described in (47) . Free concentrations in the brain were calculated by multiplying the obtained total brain concentrations with the appropriate free fractions determined by rapid equilibrium dialysis.
Behavioral assessment
The ligands and the non-selective PAM DZP were tested in behavioral tests assessing anxiety- 
Statistical analysis
All data are expressed as mean ± SEM. Data obtained from electrophysiology studies are subjected to t-tests comparing the mean to 100% of response to GABA alone. For behavioral experiments, statistical analyses were performed using one-way ANOVA and post-hoc Scheffe's or Student-Newman-Keuls test when applicable. For the EPM and YM tests, sex was put as a cofactor to investigate potential sex effects on the behavioral outcome. All values obtained after statistical analysis are provided in the Supplementary Tables S1, S2, S8, S9, S10, and S11.
RESULTS

Novel IBZD amide ligands potentiate α-containing GABAA-Rs
To assess potentiation at the different α-containing recombinant GABAA-Rs (Figure 1a-d and   Supplementary Table S1 ), the effects of four new IBZD amide ligands were compared to the response to GABA alone (EC [3] [4] [5] ). At 100nM, GL-II-74 and GL-II-75 exhibit substantial allosteric modulation at α5-GABAA-Rs, while GL-II-73 and GL-II-76 exhibited lower, but still significant, potentiation (t-test comparison to 100%; t>2.9; p<0.04). At this low concentration, all compounds also potentiate α1, α2 and α3-GABAA-Rs (t>2.9; p<0.04), GL-II-75 already exhibiting high potentiation at this subunits, suggesting shared electrophysiological properties with the referent non-selective PAM DZP (48, 49) . The profiles at 100nM were confirmed at 1µM concentration, with strong α5-PAM effects (t-test comparison to 100%; t>4.67; p<0.009), and still significant potentiation at α1,α2 and α3 (t>3.17; p<0.03). ANOVA comparing potentiations between all subunits for each compound at each concentration revealed that all compounds but GL-II-75 preferentially potentiate α5-GABAA-Rs (ps<0.04; Supplementary Table S2 
Ligands selection and doses validation for animal studies
Liver microsome metabolism assays ( Supplementary Table S4 ) indicated that GL-II-73 and GL-II-74 had the longest half-lives in mouse and human, respectively, while GL-II-76 had a very short half-life in mice, precluding its use in vivo, hence it was excluded from further analysis.
Considering the potential implication of the α5-subunit on cognitive functions, and the role of α1-subunit in sedation, we aimed at finding a dose that would potentiate α5-GABAA-Rs preferentially to α1-GABAA-Rs (26) . The concentration-response curves for the ligands (Figure   1i -k and Supplementary Table S5 ) suggest that at 1mg/kg, expected potentiation would be below 120% for GL-II-73 and GL-II-75 at both α1-and α5-GABAA-Rs, while GL-II-74 would have significant potentiation at α5-GABAA-Rs. At 10mg/kg, potentiation would significantly increase for both subunits, with higher potentiation at α5-than α1-GABAA-Rs for GL-II-73 and GL-II-74. Conversely, GL-II-75 exhibits higher potentiation at α1-than at α5-GABAA-Rs at 10mg/kg. Higher potentiation at α1-than α5-GABAA-Rs was also observed with the nonselective referent DZP (Figure 1l) .
Potentiation of GABA-induced chloride current does not necessarily correlate with binding affinity. Indeed, binding assays at α1/2/3/5-GABAA-Rs showed that all ligands are affinityselective to the α5-GABAA-R (Ki values being 6-15x more potent at α5-GABAA-R than other α-GABAARs, Supplementary Table S6) . Notably, GL-II-73 showed the lowest affinities, with Ki values in the µM range, compared to the other ligands. In contrast to all four novel ligands, DZP showed high and similar affinities at all α-GABAA-Rs.
Together, these results establish GL-II-73, GL-II-74 and GL-II-75 as ligands with significant PAM efficacies at α5-GABAA-Rs, and low, moderate and higher efficacies at α1/2/3-GABAA-Rs, respectively, and also as α5-GABAA-R-binding preferring ligands, possessing relatively high affinities, with the notable exception of the low µM range for GL-II-73.
Pharmacokinetic, plasma stability and free fraction studies
Pharmacokinetic profiles of the test ligands and DZP were established in mice after 10mg/kg i.p. administration (Figure 2a-d) . Plasma and brain free fractions were 20.39% and 12.14% for GL-II-73, 6.34% and 4.49% for GL-II-74, 5.08% and 1.34% for GL-II-75, and 16.25% and 6.38% for DZP, respectively. Elimination half-lives (T 1/2 ) of all three ligands and DZP suggest that DZP and GL-II-74 are the most stable in mouse plasma, while GL-II-73 is most stable in the mouse brain. Maximum brain concentration (C max ) was the highest with GL-II-74, suggesting a relatively optimized capacity for brain targeting. Brain-to-plasma partition coefficient (K p ) values showed that GL-II-74 displayed excellent brain permeability, although less efficient than DZP (Kp=1.14 vs 3.06). This is further supported by the ratio of unbound brain to unbound plasma ligand concentrations values (K p,uu ), a measure of net transport across the blood-brain barrier, which better quantifies the brain penetration efficiency (53) . This parameter demonstrates that GL-II- Figure S2 and Supplementary Table S7) demonstrated that attainable concentrations were governed by the dose and dosage regimen. In view of the potentiation at α1-and α5-GABAA-Rs (Figure 1 ) and pharmacokinetic properties (Figure 2) , doses of 1, 5 and 10mg/kg doses were chosen for behavioral testing.
Estimated in vivo receptor occupancy
The relative fraction of receptors occupied at the given free concentration can be approximated from in vitro binding and PK data (Supplementary Table S7 ). At 10mg/kg, GL-II-73 displayed very low predicted receptor occupancy, including at the α5-GABAA-R (5.95%). GL-II-75
displayed low values at α1/2/3-GABAA-Rs (<9.31%), and 38.42% predicted occupancy at α5-GABAA-Rs. GL-II-74 displayed values in the 17-24% range for α1/2/3-GABAA-Rs and 75.51% for α5-GABAA-Rs. In contrast, DZP displayed a much greater overall occupancy at all four α5-GABAA-R (70% and above), even at the 1.5mg/kg low dose. Despite these variable predicted receptor occupancy levels, we used the electrophysiological responses at α1-and α5-GABAARs as guide for in vivo studies.
Effects of novel IBZD amide ligands with α5-PAM activity on locomotor activity
The effects of GL-II-73, GL-II-74 and GL-II-75, dosed i.p. at 10mg/kg were assessed on the Figure S4) , confirming its known sedative effect on spontaneous locomotor activity. At contrary, GL-II-73 had no effect on locomotor activity. Figures S5) , thus precluding any conclusion as to putative depressant-like effect.
The novel IBDZ amide ligands exhibit anxiolytic and antidepressant-predictive properties
The novel IBZD amide ligands reverse stress-induced working memory deficits
ANOVAs reveled differences in alternation rate after CS exposure and injection of the ligands (F>7; p<0.0004). Young adult mice were exposed to chronic stress (CS) to induce working memory impairments in a YM spatial spontaneous alternation task. CS exposure decreased the alternation rate in animals receiving only vehicle (p<0.002; Figures 4A-D and Supplementary Table S9 ). Administration of GL-II-73 at 10mg/kg restored alternation rate in stressed animals to the same level as non-stressed animals, and significantly different from the stressed mice receiving vehicle (p=0.01). 1mg/kg and 5mg/kg doses were inefficient. In contrast, stressed animals injected with GL-II-74 displayed lower alternation rate than non-stressed animals, suggesting a lack of pro-cognitive effect, regardless of the ligand dose (p>0.97). GL-II-75 administration restored alternation rate to non-stressed levels at 5 and 10mg/kg (p<0.045). As expected, the administration of 1.5mg/kg of DZP did not reverse the cognitive deficits induced by CS (p=0.94).
We also tested the ligands in non-stressed animals to assess putative effects at baseline (Supplementary Figure S6 and Supplementary Table S9) . GL-II-73 and GL-II-75 had no effect on alternation rate (ANOVAs F<2.4, p>0.3), whereas 10mg/kg of GL-II-74 and 1.5mg/kg DZP reduced alternation rates (ANOVAs F>8.8; p<0.005), suggesting deleterious effects on working/spatial memory.
GL-II-73 and GL-II-75 reverse age-related working memory deficits
The pro-cognitive efficacy of GL-II-73 and GL-II-75 was assessed in old male mice. ANOVAs reveled significant differences between young, old and old treated (F<0.0015). 18-month old mice displayed alternation rates in the Y-maze at chance level, suggesting cognitive impairment 
DISCUSSION
The present study identified for the first time the combined antidepressant, anxiolytic and procognitive properties of newly designed IBDZ amide ligands with α5-PAM activity. This work is based on the hypotheses that deficits in signaling through these receptors contribute to mood and cognitive symptoms in depression and during aging, and that selective enhancement of activity at α5-GABAA-Rs may have therapeutic potential, compared to non-selective BZs that lack such activities. We generated four ligands; metabolic stability of one of them (GL-II-76) was unfavorable, potentially due to the pyrrolidine residue in the amide moiety, and it was not tested further. Binding and electrophysiological assessment indicated that GL-II-73 and GL-II-74 acted as PAMs with priority affinity and efficacy at α5-GABAA-Rs, whereas GL-II-75 potentiated GABA-gated chloride current to a greater extent at α1-, α2-and α3-GABAA-Rs compared to α5-GABAA-R, suggesting properties closer to DZP (48), although with much lower affinity at α-GABAA-Rs than DZP. The lack of potentiation at GABAA-Rs containing the α4, α6 or δ subunits (54) supports the notion that all ligands bind to the DZP-specific BZ-sensitive site of GABAA-Rs.
Brain and plasma pharmacokinetic studies showed that the ligands are brain-penetrant, with penetration indices (K p , K p,uu ) ranked in the following decreasing order: DZP > GL-II-74 > GL-II-75 > GL-II-73. Accordingly, all ligands were tested for behavioral activity in vivo. The three newly-designed ligands as well as the non-selective DZP (55) exerted an anxiolytic effect, demonstrating conserved anxiolytic effects despite variable efficacy profiles, probably attributable to a sufficient degree of modulatory activity at α2-GABAA-Rs (27) . In the forcedswim test, all three new ligands displayed antidepressant-like properties, at doses that induced no or low locomotor effects. GL-II-74 and GL-II-75 demonstrated altered locomotor activity and diminished coordination at the higher doses (10mg/kg), suggesting motor-impairing side-effects, probably due to their higher potentiation at α1-GABAA-Rs (56, 57) . On the other hand, the affinity of GL-II-73 for α1-GABAA-Rs is exceptionally low, which profoundly decreases the propensity of this ligand to elicit any motor impairment. In contrast, DZP increased the time spent immobile, confirming a lack of antidepressant effect, or even an induction of depressantlike state, although the latter was probably confounded by motor-impairing effects (58) .
We tested the potential of novel ligands at reversing spatial working memory deficits induced by chronic stress exposure (14, 59) or related to normal aging (60, 61) . GL-II-73 and GL-II-75 exhibited significant pro-cognitive efficacy in the stress-induced cognitive deficit model, whereas GL-II-74 displayed no pro-cognitive effects. Notably, the pro-cognitive effects of GL-II-73 and GL-II-75 were confirmed in aged mice, as old animals performed at levels observed in young animals after a single injection. The pro-cognitive effect of GL-II-73, but not GL-II-75, was maintained after sub-chronic administration in both the stress-induced and aging models. It remains to be tested whether this difference reflected the shorter brain half-life or other kinetic parameters of GL-II-75, or a potential desensitization effect. Consistent with previous findings, DZP had no pro-cognitive effects (62) . Together, these results demonstrate for the first time the potential for anxiolytic and combined antidepressant and pro-cognitive properties of newly designed IBDZ amide ligands with efficacy at α5-GABAA-Rs.
It was recently shown that co-localization of the α1-, α5-and γ2-subunit in the hippocampus is necessary for successful spatial learning (26) . From this postulate, the potentiation at both α5-and α1-GABAA-Rs could explain pro-cognitive properties of GL-II-73 and GL-II-75 after acute/sub-chronic administration in our working memory task, however it does not explain the lack of pro-cognitive effects of GL-II-74 and of BZs in general. Moreover, it was shown in experiments combining DZP with α5-or α1-GABAA-R antagonists that DZP incapacitation action in the Morris water maze, a reference spatial learning and memory test (63) , are mediated by α1-GABAAR activation and that blockade of α5-GABAAR activity further worsen this incapacitation.
Could all these apparently disparate findings be reconciled in a consistent way in light of other parameters tested or estimated in this study? We suggest that the relative fraction of receptors occupied may be a relevant factor ( Table 1) . Despite significant efficacy and robust behavioral effects, GL-II-73 displayed unprecedented low overall receptor occupancies, compared to GL-II-74, GL-II-75 and DZP. This suggests that a low fractional occupancy at α1-GABAA-Rs (<10%, and preferentially <1%), accompanied by a moderate level of positive modulation at both α1-and α5-GABAA-Rs, gives rise to an improved side-effect profile, together unmasking antidepressant or pro-cognitive potential of α5-GABAA-Rs. Hence, high fractional occupation may preclude any antidepressant or pro-cognitive properties, consistent with the prodepressant-like(55) and amnesic effect of DZP (64) suggested to be mediated by α1-GABAA-Rs (65, 66) . The role of the α1-and α5-subunit seems to follow a biphasic pattern, where low activation facilitates mood and cognitive processes whereas high and sustained activation impairs these functions (67) .
Negative allosteric modulators (NAMs) at GABAA-Rs can also exert antidepressant (68) and pro-cognitive (69, 70) activity in tests such as passive avoidance learning, recognition learning (71) and spatial memory (72) . Moreover, patients with cognitive impairment in Down syndrome were unsuccessfully clinically-trialed with the α5-selective NAM basmisanil, which is currently being tested for cognitive impairment associated with schizophrenia (73) . However, reducing the function of α5-GABAA-Rs is predicted to worsen the pathology associated with reduced SOMATOSTATIN cell function and increased neuronal excitability, hence being potentially associated with risk for long-term detrimental effects, and Alzheimer's disease development (74) . However, the putative pro-cognitive properties of both α5-NAMs and α5-PAMs are not mutually incompatible. α5-NAM could be acutely efficient in certain cognitive tasks such as spatial reference (70) where disinhibition of pyramidal neurons may facilitate the acquisition of a mental spatial map. In contrast, an α5-PAM could be efficient in cognitive tasks (such as working memory) where increased inhibition of neuronal activity may reduce noise and interferences, and increase signal-to-noise ratio for incoming stimuli (6, 75) , together strengthening the salient inputs that need to be kept for high-level performances (76) . This hypothesis on the roles of NAMs and PAMs will require further validation.
Given the increased rates of cognitive and mood impairments with psychiatric diseases and aging, it is imperative to develop new therapeutic strategies based on emerging knowledge of primary pathologies of the diseases. Here, we designed, developed, tested and validated preclinical efficacies of novel IBZD amide ligands acting either preferentially (GL-II-73 and GL-II- 
